https://sputniknews.in/20240209/indias-indigenous-cancer-treatment-car-t-cell-therapy-cures-its-first-patient-6501400.html
India's Indigenous Cancer Treatment 'CAR-T Cell Therapy' Cures Its First Patient
India's Indigenous Cancer Treatment 'CAR-T Cell Therapy' Cures Its First Patient
Sputnik India
CAR-T cell therapy, a revolutionary treatment, was given the green light for commercial use by India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), last year.
2024-02-09T20:11+0530
2024-02-09T20:11+0530
2024-02-09T20:11+0530
science & tech
india
health
delhi
health crisis
health issues
healthcare system
the world health organization (who)
cancer
science & tech
https://cdn1.img.sputniknews.in/img/07e8/02/09/6502352_0:198:2000:1323_1920x0_80_0_0_63cede76ee84ff2ff9f1ac75e2ed0e48.jpg
India's first patient to undergo indigenous cancer treatment using 'CAR-T cell therapy', a form of immunotherapy that genetically modifies a patient's white blood cells to combat cancer cells, has been declared cancer-free.The patient, Dr. (Colonel) VK Gupta, a Delhi-based gastroenterologist, took this therapy by paying just INR 4.2 Million which would've otherwise cost him INR 40 Million abroad.The CAR-T cell therapy, also known as NexCAR19, is a groundbreaking treatment for B-cell cancers like leukaemia and lymphoma.Developed by ImmunoACT, a company that emerged from the prestigious Indian Institute of Technology Bombay (IITB) and Tata Memorial Hospital, this cutting-edge therapy offers a promising solution to those battling the diseases.Over 30 hospitals across 10 Indian cities now offer this therapy, providing treatment to eligible patients over 15 years old who are fighting B-cell cancers.
https://sputniknews.in/20230914/nanoparticles-can-detect-and-destroy-cancer-cells-indian-scientists-4238266.html
india
delhi
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2024
Sangeeta Yadav
https://cdn1.img.sputniknews.in/img/07e6/0c/0f/110602_0:0:641:640_100x100_80_0_0_c298016a79eb02ef8caa9d1f688c12a5.jpg
Sangeeta Yadav
https://cdn1.img.sputniknews.in/img/07e6/0c/0f/110602_0:0:641:640_100x100_80_0_0_c298016a79eb02ef8caa9d1f688c12a5.jpg
News
en_IN
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sangeeta Yadav
https://cdn1.img.sputniknews.in/img/07e6/0c/0f/110602_0:0:641:640_100x100_80_0_0_c298016a79eb02ef8caa9d1f688c12a5.jpg
india, indigenous cancer treatment, car-t cell therapy, patient, indigenous cancer treatment, immunotherapy, white blood cells, combat cancer cells, cancer-free, gastroenterologist, t cells, nexcar19, groundbreaking treatment, b-cell cancers, leukaemia, lymphoma, immunoact, indian institute of technology bombay (iitb), tata memorial hospital, cutting-edge therapy, battling diseases,
india, indigenous cancer treatment, car-t cell therapy, patient, indigenous cancer treatment, immunotherapy, white blood cells, combat cancer cells, cancer-free, gastroenterologist, t cells, nexcar19, groundbreaking treatment, b-cell cancers, leukaemia, lymphoma, immunoact, indian institute of technology bombay (iitb), tata memorial hospital, cutting-edge therapy, battling diseases,
India's Indigenous Cancer Treatment 'CAR-T Cell Therapy' Cures Its First Patient
CAR-T cell therapy, a revolutionary treatment, was given the green light for commercial use by India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), last year.
India's first patient to undergo
indigenous cancer treatment using 'CAR-T cell therapy', a form of
immunotherapy that genetically modifies a patient's
white blood cells to
combat cancer cells, has been declared
cancer-free.The patient, Dr. (Colonel) VK Gupta, a
Delhi-based gastroenterologist, took this therapy by paying just
INR 4.2 Million which would've otherwise cost him INR 40 Million abroad.
CAR-T cell therapy involves extracting white blood cells or T cells from the patient and altering them in the lab to produce a unique protein known as a chimeric antigen receptor (CAR).
When reintroduced to the patient, these modified cells are empowered by the CAR protein to identify and combat cancer cells.
The CAR-T cell therapy, also known as NexCAR19, is a
groundbreaking treatment for B-cell cancers like leukaemia and lymphoma.
Developed by ImmunoACT, a company that emerged from the prestigious Indian Institute of Technology Bombay (IITB) and Tata Memorial Hospital, this cutting-edge therapy offers a promising solution to those battling the diseases.
Over 30 hospitals across 10 Indian cities now offer this therapy, providing treatment to eligible patients over 15 years old who are fighting B-cell cancers.
